Your Molecule
Your Molecule
Antibodies and Antibody Formats
Antibodies and Antibody Formats
Formulation excellence for monoclonal, bispecific and engineered antibody formats — delivered as liquid or lyophilized drug products with stability, patient convenience, and manufacturability in mind.
Early risk identification to design stable, patient-ready drug products
Why antibody formats require special attention
Why antibody formats require special attention
Why antibody formats require special attention
Antibody therapeutics are foundational to modern biologics across oncology, immunology, inflammatory or metabolic diseases. Yet their molecular size, surface liabilities and, for engineered formats, asymmetric architectures, non-native interfaces can elevate risks to quality, safety and efficacy due to aggregation, viscosity-driven handling challenges, and impairment of chemical and structural integrity and loss of potency.
Dosing trends toward subcutaneous delivery further push concentrations and formulation challenges. Addressing these complexities early — with predictive tools, targeted excipient selection and fit-for-purpose study design — helps conserve precious material, compress timelines and build a robust CMC package.
Explore our full modalities hub
Antibody therapeutics are foundational to modern biologics across oncology, immunology, inflammatory or metabolic diseases. Yet their molecular size, surface liabilities and, for engineered formats, asymmetric architectures, non-native interfaces can elevate risks to quality, safety and efficacy due to aggregation, viscosity-driven handling challenges, and impairment of chemical and structural integrity and loss of potency.
Dosing trends toward subcutaneous delivery further push concentrations and formulation challenges. Addressing these complexities early — with predictive tools, targeted excipient selection and fit-for-purpose study design — helps conserve precious material, compress timelines and build a robust CMC package.
Explore our full modalities hub
Antibody therapeutics are foundational to modern biologics across oncology, immunology, inflammatory or metabolic diseases. Yet their molecular size, surface liabilities and, for engineered formats, asymmetric architectures, non-native interfaces can elevate risks to quality, safety and efficacy due to aggregation, viscosity-driven handling challenges, and impairment of chemical and structural integrity and loss of potency.
Dosing trends toward subcutaneous delivery further push concentrations and formulation challenges. Addressing these complexities early — with predictive tools, targeted excipient selection and fit-for-purpose study design — helps conserve precious material, compress timelines and build a robust CMC package.
Explore our full modalities hub
Our expertise
Our expertise
Our expertise
We support a broad range of antibody modalities: classical monoclonals, bispecifics and multispecifics, fragments (Fab, scFv), Fc-fusion proteins and co-formulations. For each, we tailor liquid or lyophilized pathways based on stability needs, primary packaging, route of administration and supply-chain realities. Programs emphasize in-depth in-silico characterization statistically sound DoE, and predictive stability modeling accompanied by robust and differentiating analytical characterization together with stringent data governance to de-risk decisions and accelerate to clinic.
We support a broad range of antibody modalities: classical monoclonals, bispecifics and multispecifics, fragments (Fab, scFv), Fc-fusion proteins and co-formulations. For each, we tailor liquid or lyophilized pathways based on stability needs, primary packaging, route of administration and supply-chain realities. Programs emphasize in-depth in-silico characterization statistically sound DoE, and predictive stability modeling accompanied by robust and differentiating analytical characterization together with stringent data governance to de-risk decisions and accelerate to clinic.
We support a broad range of antibody modalities: classical monoclonals, bispecifics and multispecifics, fragments (Fab, scFv), Fc-fusion proteins and co-formulations. For each, we tailor liquid or lyophilized pathways based on stability needs, primary packaging, route of administration and supply-chain realities. Programs emphasize in-depth in-silico characterization statistically sound DoE, and predictive stability modeling accompanied by robust and differentiating analytical characterization together with stringent data governance to de-risk decisions and accelerate to clinic.
Ready to talk about your bispecific formulation strategy?
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Key Focus Areas
-
-
Let’s Build the Right Formulation — Together
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Who its ideal for?
How we support you
Tailored formulation designs for mAbs, bsAbs, fragments and Fc-fusions, aligned with target product profile.
Data-driven excipient pre-selection and DoE set-up and execution tailored to development objectives and project constraints to conserve material and time.
Long-term stability strategies and predictive modeling to support shelf-life setting.
Experience with co-formulations and complex engineered antibody formats.
End-to-end partnership from developability and preformulation through clinical supply readiness.
Tailored formulation designs for mAbs, bsAbs, fragments and Fc-fusions, aligned with target product profile.
Data-driven DoE and excipient pre-selection to conserve material and time.
Long-term stability strategies and predictive modeling to support shelf-life setting.
Experience with co-formulations and advanced antibody formats.
How we support you?
